Trials of Prophylactic Irradiation of Tracts: What is the Appropriate End Point?

Affiliations

¹ Gérard Zalcman, MD, PhD, Hôpital Bichat, Université Paris-Diderot, Paris, France; and Solenn Brosseau, MD and Valérie Gounant, MD, CIC1425 INSERM, Hôpital Bichat-Claude Bernard, Paris, France.

Comment

Gérard Zalcman et al. J Clin Oncol. 2019.

. 2019 Oct 10;37(29):2693.

doi: 10.1200/JCO.19.00927. Epub 2019 Aug 22.

¹ Gérard Zalcman, MD, PhD, Hôpital Bichat, Université Paris-Diderot, Paris, France; and Solenn Brosseau, MD and Valérie Gounant, MD, CIC1425 INSERM, Hôpital Bichat-Claude Bernard, Paris, France.

No abstract available

Comment in

Reply to G. Zalcman et al.
Bayman N, Clive A, Maskell N, Ryder D, Taylor H, Faivre-Finn C. Bayman N, et al. J Clin Oncol. 2019 Oct 10;37(29):2694-2695. doi: 10.1200/JCO.19.01520. Epub 2019 Aug 22. J Clin Oncol. 2019. PMID: 31437093 No abstract available.

Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial.
Bayman N, Appel W, Ashcroft L, Baldwin DR, Bates A, Darlison L, Edwards JG, Ezhil V, Gilligan D, Hatton M, Jegannathen A, Mansy T, Peake MD, Pemberton L, Rintoul RC, Snee M, Ryder WD, Taylor P, Faivre-Finn C. Bayman N, et al. J Clin Oncol. 2019 May 10;37(14):1200-1208. doi: 10.1200/JCO.18.01678. Epub 2019 Mar 28. J Clin Oncol. 2019. PMID: 30920878 Clinical Trial.